[POSASR] Verve Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Verve Therapeutics, Inc. (NASDAQ: VERV) filed Post-Effective Amendment No. 3 to its automatic shelf registration (Form S-3, File No. 333-267578) to terminate the registration and deregister all unsold securities previously available under the shelf.

• The original shelf (effective Sept 23 2022) covered up to $500 million in mixed securities and an additional $150 million of common stock under an at-the-market sale agreement with Jefferies.
• On July 25 2025, Verve completed its merger with Eli Lilly and Company; Ridgeway Acquisition Corp. was merged into Verve, which now operates as an indirect wholly owned subsidiary of Lilly.
• Because the company is no longer an independent public issuer, all offerings under the shelf have been permanently terminated.

The amendment, signed by President Jonathan R. Haug, removes any remaining securities from registration, leaving zero securities effective under the shelf going forward.

Positive

• Merger with Eli Lilly closed, providing liquidity to former VERV shareholders.
• Removal of $650 million shelf eliminates potential future dilution concerns (now moot under private ownership).

Negative

• Deregistration confirms loss of independent public investment opportunity in Verve Therapeutics.
• No further public disclosures will be available, reducing transparency for any remaining minority holders of contingent rights, if any.

Insights

Securities Analyst

TL;DR: Routine deregistration after Lilly buyout; no direct valuation impact for investors.

This filing simply cleans up Verve’s capital markets footprint following the closing of its cash-out merger with Eli Lilly. The $650 million shelf is no longer needed because Verve's equity is now privately held. Investors who tendered shares have already received merger consideration, so the amendment does not alter economics or create new liabilities. From a disclosure perspective, it removes any lingering dilution overhang, but that is moot given the company’s delisting. Overall impact: administrative and neutral.

Corporate Governance Expert

TL;DR: Filing satisfies Rule 415 undertakings and finalizes Verve’s transition to private status.

The registrant is fulfilling its obligation to withdraw unsold securities under Rule 478. This signals that all public-facing compliance for Verve, aside from merger-related wrap-ups, is effectively complete. It also helps Lilly consolidate reporting streams by eliminating redundant shelf capacity. No governance red flags appear; the amendment follows standard post-merger protocol.

As filed with the Securities and Exchange Commission on July 25, 2025

Registration No. 333-267578

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 3

TO

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

VERVE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		82-4800132
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

201 Brookline Avenue, Suite 601

Boston, Massachusetts

02215

(617) 603-0070

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Jonathan R. Haug

President

Verve Therapeutics, Inc.

Lilly Corporate Center

Indianapolis, Indiana 46285

(Name and address of agent for service)

(317) 276-2000

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

Sophia Hudson, P.C.

Sharon Freiman, P.C.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, New York 10022

Telephone: (212) 446-4800

(Approximate date of commencement of proposed sale to the public): Not applicable.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No.  3 (this “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (File No. 333-267578) originally filed by Verve Therapeutics, Inc. (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) on September 23, 2022, which became effective automatically upon filing, as amended by Post-Effective Amendment No. 1 filed on February 27, 2025 and Post-Effective Amendment No. 2 filed on February 27, 2025 (the “Registration Statement”), registering (i) the offering, issuance and sale by the Registrant of up to $500,000,000 of the Registrant’s debt securities, common stock, par value $0.001 per share (“Common Stock”), preferred stock, warrants and/or units consisting of some or all of these securities, and (ii) the offering, issuance and sale by the Registrant of up to $150,000,000 of Common Stock pursuant to the Open Market Sale Agreement, dated as of July 1, 2022, by and between the Registrant and Jefferies LLC, as sales agent.

On July 25, 2025, pursuant to the Agreement and Plan of Merger, dated June 16, 2025 (the “Merger Agreement”), by and among the Registrant, Eli Lilly and Company (“Parent”) and Ridgeway Acquisition Corporation (“Purchaser”), Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and becoming an indirect wholly-owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statement. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under the Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statement and removes from registration all of the securities that remain unsold under the Registration Statement as of the date hereof, if any.

The Registrant is filing this Post-Effective Amendment to withdraw and remove from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to this Post-Effective Amendment, there will be no remaining securities registered by the Registrant pursuant to the Registration Statement.

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, Indiana, on July 25, 2025.

VERVE THERAPEUTICS, INC.
By:		/s/ Jonathan R. Haug
Name:		Jonathan R. Haug
Title:		President

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment.

FAQ

Why did Verve Therapeutics file Post-Effective Amendment No. 3?

To deregister all unsold securities under its $650 million shelf because the company became a wholly owned subsidiary of Eli Lilly.

How much in securities were removed from registration?

Up to $500 million in mixed securities plus $150 million of common stock under an ATM program.

When did the Eli Lilly merger with VERV close?

The merger closed on July 25 2025.

Is Verve Therapeutics still publicly traded after this filing?

No. Following the merger, Verve is an indirect wholly owned subsidiary of Eli Lilly and is no longer an independent public company.

Will there be future offerings under the deregistered shelf?

No. The amendment terminates the shelf's effectiveness; no securities remain registered.

Who signed the Post-Effective Amendment on behalf of Verve?

The filing was signed by Jonathan R. Haug, President of Verve Therapeutics.